Key result
Visceral adipose tissue measurement sites at L1-L2 and L2-L3 were not significantly better predictors of metabolic syndrome compared to L4-L5 (L2-L3 OR 2.68; 95% CI 1.6-4.4 vs L4-L5 OR 2.56).
Why the study?
Does the measurement site of visceral adipose tissue impact the prediction of metabolic syndrome in overweight or obese postmenopausal women?
Observational (n=67)
Does the measurement site of visceral adipose tissue impact the prediction of metabolic syndrome in overweight or obese postmenopausal women?
Answers are grounded in this paper and cite their sources.
Although measurement site impacts the prediction of VAT volume, it does not improve the prediction of metabolic syndrome, supporting the continued use of L4-L5 for assessing metabolic risk.
The associations between visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT) and metabolic risk may be influenced by measurement site. The aim of this study was to compare the strength of the associations between VAT and ASAT, as assessed by a cross-sectional image (area) or total volume, and prevalent metabolic syndrome (MetS). We also examined the association between changes in abdominal AT area and volume with concomitant changes in metabolic risk. Abdominal AT volume and areas were derived using ~35 continuous computed tomography (CT) images from T10-T11 to L5-S1 in overweight or obese postmenopausal women before (n = 67) and after (n = 39) a 6-month exercise intervention. At baseline, measurement site did not influence the inter-relationship between ASAT area and total volume, and between ASAT and MetS. Conversely, VAT areas at L1-L2 and L2-L3 were stronger correlates of VAT volume at baseline (L1-L2 (r = 0.94), L2-L3 (r = 0.95), L4-L5 (r = 0.89)) and changes therein (L1-L2 (r = 0.77), L2-L3 (r = 0.75), L4-L5 (r = 0.55)) as compared to L4-L5, but were not significantly better predictors of MetS as compared to L4-L5 or the total volume (L2-L3: odds ratio (OR) = 2.68 (1.6-4.4), L1-L2: OR = 1.88 (1.2-3.0), L4-L5: OR = 2.56 (1.6-4.1), volume: OR = 2.07 (1.1-3.8)). Changes in VAT and ASAT were not associated with changes in MetS (P > 0.10). Although measurement site has an impact on the prediction of VAT volume, this does not translate into an improved prediction for the MetS. Thus, there is not enough evidence to support changing the current research practice of assessing VAT volume or at L4-L5 for the prediction of metabolic risk.
No takes yet. Share an insight, caveat, or question.
Kuk et al. (2009) conducted an observational in Overweight or obesity with metabolic risk (n=67). Visceral adipose tissue measurement at L1-L2 or L2-L3 vs. Measurement at L4-L5 or total volume was evaluated on Prevalent metabolic syndrome (MetS) (OR 2.68, 95% CI 1.6-4.4). Visceral adipose tissue measurement sites at L1-L2 and L2-L3 were not significantly better predictors of metabolic syndrome compared to L4-L5 (L2-L3 OR 2.68; 95% CI 1.6-4.4 vs L4-L5 OR 2.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: